

Amy Goodrich: Objectives

Upon completion of this activity, participants will be able to:

- Review updated efficacy and safety data associated with novel agent classes and other emerging therapies in B-cell lymphoma, including BTK and PI3K inhibitors, immunomodulators, antibodies, BCL-2 inhibitors, and CAR-T cell therapy, among others
- Cite dosage, administration strategies, and treatment schedules of novel agent classes for the management of newly diagnosed or refractory/relapsed B-cell lymphoma
- Apply successful patient educational strategies related to novel therapies and ongoing clinical trials to increase compliance with and adherence to novel regimens for B-cell lymphoma
- Utilize effective side effect prevention and management strategies related to novel therapies in patients with B-cell malignancies